Genetic blood test could spare many pregnancies from unnecessary monitoring
NCT ID NCT07715214
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study tests whether a blood test using next-generation sequencing (NGS) can accurately determine the blood type of an unborn baby. In about 1% of pregnancies, the mother's immune system produces antibodies that can attack the baby's red blood cells, potentially causing anemia or other serious complications. Current methods to assess risk are imperfect, leading to unnecessary monitoring in about 30% of cases. By analyzing fetal DNA from a maternal blood sample, researchers aim to reliably identify which babies are truly at risk and which are not, improving care and reducing anxiety.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- NGS analysis for fetal red cell blood type in maternal plasma
- What this could lead to
- If successful, this approach could replace current imperfect methods, allowing doctors to accurately identify which fetuses are truly at risk and avoid unnecessary monitoring for those who are not.
- What could go wrong
- This is an implementation study focused on accuracy and logistics, not a treatment trial. The technology may not prove reliable enough in all cases, and broader use would require further validation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 750 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- red blood cell alloimmunized pregnancies in the participating regions during the study period Exclusion Criteria: * Miscarriage and terminations of pregnancy for other reasons than severe alloimmunization
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HDFN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.